Publications by authors named "M Amparo Perez Tamarit"
Article Synopsis
- Tirbanibulin, a treatment for actinic keratosis (AK), is typically approved for smaller fields (up to 25 cm), but this study aimed to assess its safety and tolerability on a larger area of approximately 100 cm.
- In a Phase 3 study, 105 adult patients with multiple AKs on the face or balding scalp applied tirbanibulin daily for 5 days, with results showing common mild-to-moderate side effects like erythema and flaking, while effectiveness led to a significant reduction in AK lesions.
- The findings suggest that tirbanibulin is safe and tolerable for larger treatment areas, although the study lacked a control group and long-term follow-up data
: The coronavirus disease 2019 (COVID-19) pandemic has led to the death of almost 7 million people, however, with a cumulative incidence of 0.76 billion, most people survive COVID-19. Several studies indicate that the acute phase of COVID-19 may be followed by persistent symptoms including fatigue, dyspnea, headache, musculoskeletal symptoms, and pulmonary functional-and radiological abnormalities.
View Article and Find Full Text PDFHuman intestinal spirochetosis (HIS) can cause gastrointestinal symptoms, although asymptomatic infections have been described. Individuals from low-income countries, people living with HIV, and men who have sex with men (MSM) show increased risk. A retrospective review of all patients diagnosed with HIS (n = 165) between January 2013 and October 2020 at a tertiary hospital in Madrid, Spain, was performed to assess risk factors for symptomatic HIS, symptoms, and response to treatment.
View Article and Find Full Text PDFBackground: Onychomycosis is a difficult-to-treat fungal nail infection whose treatment can involve systemic or topical antifungal approaches.
Objectives: To assess the efficacy and safety of terbinafine 10% nail lacquer in distal-lateral subungual onychomycosis (DLSO).
Patients/methods: Patients with mild-to-moderate DLSO were randomised (3:3:1) to receive double-blind topical terbinafine 10% (n = 406) or its vehicle (n = 410) administered once daily for 4 weeks and then once weekly for 44 weeks, or open-label topical amorolfine 5% (n = 137) for 48 weeks, with a 12-week follow-up period.
Background: Oral finasteride is a well-established treatment for men with androgenetic alopecia (AGA), but long-term therapy is not always acceptable to patients. A topical finasteride formulation has been developed to minimize systemic exposure by acting specifically on hair follicles.
Objectives: To evaluate the efficacy and safety of topical finasteride compared with placebo, and to analyse systemic exposure and overall benefit compared with oral finasteride.